Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Estrogens and endometrial carcinoma.

L A Gray, W M Christopherson, R N Hoover

    Obstetrics and Gynecology
    |April 1, 1977
    PubMed
    Summary

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    COVID-19 "Rebound" associated with nirmatrelvir/ritonavir pre-hospital therapy.

    The Journal of infection·2022
    Same author

    A Case-Control Study of Fluoridation and Osteosarcoma.

    Journal of dental research·2020
    Same author

    Circulating maternal and umbilical cord steroid hormone and insulin-like growth factor concentrations in twin and singleton pregnancies.

    Journal of developmental origins of health and disease·2018
    Same author

    Optimising perioperative care for hip and knee arthroplasty in South Africa: a Delphi consensus study.

    BMC musculoskeletal disorders·2018
    Same author

    TET2 binds the androgen receptor and loss is associated with prostate cancer.

    Oncogene·2016
    Same author

    Prenatal diethylstilbestrol exposure and risk of obesity in adult women.

    Journal of developmental origins of health and disease·2015

    This study found that conjugated estrogen use significantly increases endometrial carcinoma risk, especially with longer duration and higher doses. Women using conjugated estrogens for 10+ years faced an 11.5-fold higher risk.

    Area of Science:

    • Gynecologic Oncology
    • Endocrinology
    • Epidemiology

    Background:

    • Endometrial carcinoma is a significant gynecologic malignancy.
    • Hormone replacement therapy, particularly estrogen use, has been investigated for its potential role in cancer development.

    Purpose of the Study:

    • To investigate the association between conjugated estrogen use and the risk of endometrial carcinoma.
    • To evaluate the impact of duration and dosage of estrogen use on this risk.

    Main Methods:

    • A matched case-control study design was employed.
    • 205 women with endometrial carcinoma were matched with 205 women who underwent hysterectomy for benign conditions.
    • Conjugated estrogen use, duration, and dosage were assessed for both groups.
    Keywords:
    Age FactorsBiologyCancerComparative StudiesContraceptionContraceptive Agents, Estrogen--administraction and dosageContraceptive Agents, Estrogen--side effectsContraceptive Agents, Estrogen--therapeutic useContraceptive Agents, Female--administraction and dosageContraceptive Agents, Female--side effectsContraceptive Agents, Female--therapeutic useContraceptive Agents--administraction and dosageContraceptive Agents--side effectsContraceptive Agents--therapeutic useDemographic FactorsDiseasesEndocrine SystemEndometrial CancerEstrogens--administraction and dosageEstrogens--side effectsEstrogens--therapeutic useFamily PlanningHormonesHysterectomyLongterm EffectsMenopauseNeoplasmsParityPhysiologyPopulationPopulation DynamicsResearch MethodologyStudiesTime FactorsUterine Effects

    Related Experiment Videos

    Main Results:

    • Conjugated estrogen use was associated with a 3.1-fold increased relative risk of endometrial carcinoma (P = 0.0008).
    • Risk escalated with duration of use, reaching an 11.5-fold increase for users of 10 years or more.
    • Higher dosage (1.25 mg tablets) correlated with a 12.7-fold increased risk compared to lower doses.

    Conclusions:

    • Conjugated estrogen use is a significant risk factor for endometrial carcinoma.
    • Both the duration and dosage of conjugated estrogen therapy are critical determinants of cancer risk.